Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) is among the top losers of the stock market today, sinking -4.11% or (-0.02 points) to $0.63 from its previous close of $0.65. Does this decline mean it the best stock to buy right now? The shares seem to have an active trading volume day with a reported 120122 contracts so far this session. ADMP shares had a relatively better volume day versus average trading capacity of 757.12 thousand shares, but with a 60.53 million float and a -3.15% run over a week, it’s definitely worth keeping an eye on. The one year price forecast for ADMP stock indicates that the average analyst price target is $3.37 per share. This means the stock has a potential increase of 434.92% from where the ADMP share price has been trading recently which is between $0.6355 and $0.6858. There are some brokerage firms that offer lower targets than the average, with one of them, even setting their price target at $1.1. Flipping the other side of the coin, an analyst who is fully bullish set a price target as high as $6.
During the recent trading session for Adamis Pharmaceuticals Corporation (NASDAQ:ADMP), the company witnessed their stock drop by $-0.02 over a week and tumble down $-0.26 from the price 20 days ago. When compared to their established 52-week high of $3.29, the high they recorded in their recent session happens to be lower. Their established 52-week high was attained by the company on 02/26/19. The recent low of $0.62 stood for a -80.91% since 01/10/19, a data which is good for most investors who are looking to take advantage of the stock’s recent rise. A beta of 1.36 is also allocated to the stock. Since the beta is greater than one, it implies that the stock is more volatile than the market, a data that traders are keeping close attention to. At the moment, the median target price for ADMP is set at $3.5, a figure which is above the recent 1-year high the stock witnessed.
Looking at the current readings for Adamis Pharmaceuticals Corporation, the two-week RSI stands at 27.3. This figure suggests that ADMP stock, for now, is overbought, meaning that the shares are not stable in terms of price movement. The stochastic readings, on the other hand, based on the current ADMP readings is similarly very revealing as it has a stochastic reading of 20.89% at this stage. This figure means that ADMP share price today is being overbought.
Technical chart claims that Adamis Pharmaceuticals Corporation (ADMP) would settle between $0.68/share to $0.71/share level. However, if the stock price goes below the $0.63 mark, then the market for Adamis Pharmaceuticals Corporation becomes much weaker. If that happens, the stock price might even plunge as low as $0.61 for its downside target. The stock is currently in the red zone of MACD, with the indicator reading -0.02. Traders are always alerted for the move of a stock above or below the zero line due to the fact that the reading is an indicator of the position of the short-term average relative to the long-term average. If the MACD is above the zero line, then the short-term average relative is above that of the long-term average, thus implying an upward momentum. Vice versa is the case if the MACD is below the zero line.
Analysts at B. Riley FBR lowered their recommendation on shares of ADMP from Neutral to Sell in their opinion released on July 16. B. Riley FBR analysts have lowered their rating of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) stock from Buy to Neutral in a separate flash note issued to investors on November 12. Analysts at Maxim Group are sticking to their Buy stance. However, on May 11, they lifted price target for these shares to $10 from $5.
ADMP equity has an average rating of 2.38, with the figure leaning towards a bullish end. 3 analysts who tracked the company were contacted by Reuters. Amongst them, 1 rated the stock as a hold while the remaining 2 were split even though not equally. Some analysts rate the stock as a buy or a strong buy while no rated it as a sell. 2 analysts rated Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) as a buy or a strong buy while not a single analyst advised that investors should desist from purchasing the stock or sell them if they already own the company’s stock.
Adamis Pharmaceuticals Corporation (ADMP)’s current-quarter revenues are projected to climb by nearly 62.5% to hit $6.23 million, based on current consensus estimate. The firm’s full-year revenues are expected to expand by over 51% from $15.09 million to a noteworthy $22.78 million. At the other end of the current quarter income statement, Adamis Pharmaceuticals Corporation is expected to see its adjusted earnings surge by roughly 52.4% to hit $-0.1 per share. For the fiscal year, ADMP’s earnings are projected to climb by roughly 48% to hit $-0.52 per share.